Coagulation Factor Deficiency Market to Witness Significant Innovation and Growth by 2034
The Coagulation Factor Deficiency market is evolving rapidly, fueled by advances in gene therapy, long-acting clotting factors, and better prophylaxis. DelveInsight's report covers epidemiology and treatments for Hemophilia A, B, and rare factor deficiencies (FVII, FXI, FXIII). AAV-based gene therapies are driving new treatment goals and improving outcomes, especially for underserved patients.
DelveInsight's ' Coagulation Factor Deficiency Market Report ' delivers detailed analysis of market dynamics, historical and forecasted epidemiology, and emerging therapies across the 7MM (US, EU5, and Japan), highlighting key players and trends driving this rare disease segment.
Some of the Key Facts of the Coagulation Factor Deficiency Market Report:
• In 2023, the coagulation factor deficiency market in the 7MM was valued at approximately USD 13.5 billion.
• The US led the market, contributing around USD 7.2 billion.
• There were about 105K prevalent cases across the 7MM, with the US accounting for nearly 34K.
• Hemophilia A was the most common subtype among all coagulation factor deficiencies.
• Marketed drugs for coagulation factor deficiency include ESPEROCT (Novo Nordisk), JIVI (Bayer), and WILATE (Octapharma).
• In March 2025, the FDA approved QFITLIA (fitusiran) for routine prophylaxis to reduce bleeding episodes in patients (12+) with hemophilia A or B, with or without factor VIII or IX inhibitors.
• In December 2024, Novo announced that the FDA approved concizumab, its tissue factor pathway inhibitor (TFPI) antagonist, as a once-daily treatment to prevent or reduce bleeding episodes in patients aged 12 and older with hemophilia A or B with inhibitors.
• In October 2024, Novo Nordisk received support from European regulators for the approval of its anti-TFPI antibody, Alhemo (concizumab), as a preventive treatment for hemophilia. The company stated that, if approved, this therapy would provide the first subcutaneous prophylactic treatment to be administered once daily for individuals with hemophilia A or B who have inhibitors.
• In March 2024, ReciBioPharm signed a collaboration agreement with GeneVentiv Therapeutics, a preclinical gene therapy company, to advance the development of an adeno-associated virus (AAV)-based universal gene therapy for hemophilia, and reportedly the first to treat hemophilia patients with inhibitors.
• Emerging coagulation factor deficiency drugs include Concizumab, Fidanacogene Elaparvovec, RG6357 (SPK-8011), Fitusiran, Marstacimab, Giroctocogene Fitelparvovec, NNC0365-3769 A (MIM8), BT524, SerpinPC, STSP-0601, Marzeptacog Alfa, AB023, BAY2599023, OPK88005, and others.
• Leading companies in the coagulation factor deficiency market include Novo Nordisk, Pfizer, Spark Therapeutics, Roche, Sanofi (Genzyme), Alnylam Pharmaceuticals, Sangamo Therapeutics, Biotest AG, Centessa Pharmaceuticals (ApcinteX), Staidson Biopharma Inc., GC Biopharma, Aronora, Inc., Bayer, Ultragenyx Pharmaceutical, OPKO Health, Inc., and others.
• The rising incidence of coagulation factor deficiencies, along with ongoing advancements in treatment options, is driving the demand for more effective therapies for these conditions.
To know in detail about the coagulation factor deficiency market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Coagulation Factor Deficiency Market Forecast
Coagulation Factor Deficiency Overview
Coagulation factor deficiencies, also referred to as bleeding or clotting disorders, are a group of inherited or acquired conditions caused by the absence or dysfunction of specific proteins that are essential for blood clotting. These proteins, known as coagulation factors, are vital for halting bleeding by forming clots to close off damaged blood vessels.
There are 13 coagulation factors, each numbered from I to XIII, that work together in a complex process to maintain hemostasis. Deficiencies in any of these factors can lead to abnormal bleeding, with severity varying based on the specific factor affected and the extent of the deficiency.
Get a free sample of the coagulation factor deficiency market report with key insights and emerging therapies here:
Coagulation Factor Deficiency Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Coagulation Factor Deficiency Epidemiology Segmentation:
The coagulation factor deficiency epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:
• Total diagnosed prevalent cases
• Factor-specific prevalent cases
Download the report to understand which factors are driving coagulation factor deficiency epidemiology trends @ Coagulation Factor Deficiency Epidemiology Forecast
Coagulation Factor Deficiency Drugs Uptake, and Pipeline Development Activities
The coagulation factor deficiency drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the coagulation factor deficiency market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug.
Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share.
The report further delves into the coagulation factor deficiency pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies.
Coagulation Factor Deficiency Market Strengths
• New gene therapies for coagulation factor deficiencies, like Hemophilia A and B, offer potential long-term or curative solutions.
• Better awareness and diagnostic tools are enabling earlier detection and more effective management.
Coagulation Factor Deficiency Market Weaknesses
•Many therapies, particularly gene therapies, remain expensive, limiting accessibility.
• Advanced therapies are not widely accessible in lower-income regions due to cost and healthcare limitations.
Scope of the Coagulation Factor Deficiency Market Report
• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Coagulation Factor Deficiency Therapies: Concizumab, Fidanacogene Elaparvovec, RG6357 (SPK-8011), Fitusiran, Marstacimab, Giroctocogene Fitelparvovec, NNC0365-3769 A (MIM8), BT524, SerpinPC, STSP-0601, Marzeptacog Alfa, AB023, BAY2599023, OPK88005, and others.
• Key Coagulation Factor Deficiency Companies: Novo Nordisk, Pfizer, Spark Therapeutics, Roche, Sanofi (Genzyme), Alnylam Pharmaceuticals, Sangamo Therapeutics, Biotest AG, Centessa Pharmaceuticals (ApcinteX), Staidson Biopharma Inc., GC Biopharma, Aronora, Inc., Bayer, Ultragenyx Pharmaceutical, OPKO Health, Inc., and others.
• Coagulation Factor Deficiency Therapeutic Assessment: Coagulation factor deficiency, currently marketed, and coagulation factor deficiency emerging therapies
• Coagulation Factor Deficiency Market Dynamics: Coagulation factor deficiency market drivers and Coagulation Factor Deficiency market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Coagulation Factor Deficiency Unmet Needs, KOL's views, Analyst's views, Coagulation Factor Deficiency Market Access and Reimbursement
To learn more about the key players and advancements in the coagulation factor deficiency treatment landscape, visit the Coagulation Factor Deficiency Market Analysis Report
Table of Contents
1. Coagulation Factor Deficiency Market Report Introduction
2. Executive Summary for Coagulation Factor Deficiency
3. SWOT analysis of Coagulation Factor Deficiency
4. Coagulation Factor Deficiency Patient Share (%) Overview at a Glance
5. Coagulation Factor Deficiency Market Overview at a Glance
6. Coagulation Factor Deficiency Disease Background and Overview
7. Coagulation Factor Deficiency Epidemiology and Patient Population
8. Country-Specific Patient Population of Coagulation Factor Deficiency
9. Coagulation Factor Deficiency Current Treatment and Medical Practices
10. Coagulation Factor Deficiency Unmet Needs
11. Coagulation Factor Deficiency Emerging Therapies
12. Coagulation Factor Deficiency Market Outlook
13. Country-Wise Coagulation Factor Deficiency Market Analysis (2020–2034)
14. Coagulation Factor Deficiency Market Access and Reimbursement of Therapies
15. Coagulation Factor Deficiency Market Drivers
16. Coagulation Factor Deficiency Market Barriers
17. Coagulation Factor Deficiency Appendix
18. Coagulation Factor Deficiency Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
5 hours ago
- Globe and Mail
B.C. launches $5-million ad campaign to recruit American doctors, nurses
British Columbia has launched a six-week, $5-million campaign of targeted advertisements to recruit doctors and nurses in the United States, citing 'chaos' under the Trump administration to lure them north. The Ministry of Health said the campaign launched on Monday was being shown on thousands of advertising screens in Washington, Oregon and California, at locations within a 16-kilometre radius of health care facilities, as well as on podcasts and Netflix shows. B.C. Health Minister Josie Osborne said at a news conference it was a step B.C. needed to 'take right now' to attract physicians, nurses and other health care workers, and the province would do everything in its power to ease their transition. 'This will help supercharge our overall recruitment campaign to attract U.S. health care workers to B.C.,' she said. Opinion: How to win a trade war Fentanyl czar focused on combatting opioid trade, despite tariff distraction In one of the ads, a disgruntled-looking woman in hospital scrubs listens to 'more news from Washington' before the scene cuts to outdoor views of British Columbia, and listeners are urged to 'follow your heart' to the province. Osborne said the campaign was expected to reach about 250,000 health care workers. She said B.C. was 'taking advantage of the uncertainty and chaos' in the United States after the election of President Donald Trump by reaching out to health workers who shared the values of the province's health care system. One ad says recruits can 'practice evidence-based care' in B.C., while another promises 'universal health care that puts people first.' Looming over these efforts is the question of whether B.C.'s public single-payer system offers sufficient financial incentives. Osborne said it was difficult to directly compare physician salaries in B.C. with those in the United States. 'But I can say that with some of the recent changes we've made, and how we pay family doctors, we know that we have competitive salaries,' she said. 'We also know that we offer very competitive salaries for nursing. We offer some of the highest nursing wages in Canada. We also know, though, that doctors are not just motivated by dollars and cents.' Osborne said nearly 1,600 health care providers had already expressed an interest in moving to B.C. even before the ads launched. These included 700 doctors and 500 nurses, but she could not say how many had made it to B.C. 'We're going to do everything we can to attract as many physicians and nurses as possible,' she said without giving a specific target number. 'Ultimately, the success is measured by what people experience in their communities,' she added. She said B.C. would eventually expand international recruitment to other jurisdictions, likening the process to hitting a target. 'We've got the U.S. right in the centre, the bull's eye, and then right outside in the next rings, are countries like the United Kingdom,' she said. 'That's where we'll be focusing our efforts next.'
CTV News
7 hours ago
- CTV News
B.C. targets U.S. doctors and nurses with recruitment ads near American hospitals
B.C. Minister of Health Josie Osborne in a file photo in Burnaby, B.C., on Monday, June 10, 2024. (Darryl Dyck / The Canadian Press) British Columbia has launched a six-week, $5-million campaign of targeted advertisements to recruit doctors and nurses in the United States. The Ministry of Health says the campaign launched on Monday is being shown on thousands of advertising screens in Washington, Oregon and California, at locations within a 16-kilometre radius of health-care facilities, as well as on podcasts and Netflix shows. B.C. Health Minister Osborne says it's a step B.C. needs to 'take right now' to attract physicians, nurses and other health care workers, and the province will do everything in its power to ease their transition. In one of the ads, a disgruntled-looking woman in hospital scrubs listens to 'news from Washington' before the scene cuts to outdoor views of British Columbia, and listeners are urged to follow their hearts to the province. Osborne says B.C. is 'taking advantage of the certainty and chaos' in the United States after the election of President Donald Trump by reaching out to health workers who share the values of the province's health care system. One ad says recruits can 'practice evidence-based care' in B.C., while another promises 'universal health care that puts people first.' Osborne says nearly 1,600 health-care providers have already expressed an interest in moving to B.C. even before the ads launched, including 700 doctors and 500 nurses, but she could not say how many have made it to B.C. She says B.C. will eventually expand its international recruitment to other jurisdictions, including the United Kingdom. This report by Wolfgang Depner of The Canadian Press was first published June 6, 2025.
Globe and Mail
8 hours ago
- Globe and Mail
Dr. Louis Krenn Scholarship for Medical Students Invites Future Physicians to Share Their Vision for the Future of Medicine
The Dr. Louis Krenn Scholarship for Medical Students is officially open for applications, offering undergraduate and medical students across the United States a meaningful opportunity to reflect on their journey into healthcare and articulate their aspirations for shaping its future. Springfield, Missouri - The Dr. Louis Krenn Scholarship for Medical Students is officially open for applications, offering undergraduate and medical students across the United States a meaningful opportunity to reflect on their journey into healthcare and articulate their aspirations for shaping its future. This scholarship initiative, personally established by Dr. Louis Krenn, aims to recognize students who demonstrate a deep sense of purpose and commitment to a career in medicine. This scholarship is not limited by geographic boundaries and welcomes submissions from eligible applicants throughout the United States. With a one-time award of $1,000, the Dr. Louis Krenn Scholarship for Medical Students supports future doctors in their academic and professional pursuits, offering not only financial assistance but also recognition of their dedication to service, innovation, and compassion. To qualify, applicants must be currently enrolled as undergraduate or medical students within the United States and must be actively pursuing a pre-med or medical school track. Each applicant is required to submit a personal essay addressing the following prompt: ' Medicine is more than a career—it's a calling. What inspired you to pursue a path in healthcare, and how do you hope to shape the future of medicine through your work? ' Essays must range between 500 and 800 words. Submissions will be evaluated based on originality, insight, and alignment with the core values that have guided Dr. Louis Krenn's career: service to others, innovative thinking, and compassionate care. Dr. Louis Krenn is a respected Family Medicine physician with more than two decades of clinical practice and leadership experience. Based in Springfield, Missouri, Dr. Louis Krenn has held key roles in clinical efficiency, telehealth expansion, and medical education. His impact at CoxHealth and his mentorship of emerging healthcare professionals reflect a lifelong dedication to improving patient care and shaping the future of medicine. Over the years, Dr. Louis Krenn has not only practiced medicine but also led transformative projects in healthcare delivery. His efforts in clinical process improvement and his advocacy for telemedicine have set a forward-looking example for aspiring doctors. Through this scholarship, Dr. Louis Krenn continues his commitment to mentoring the next generation of healthcare professionals. Applicants are encouraged to visit the official scholarship website to review eligibility and submission requirements: The deadline for submission is March 15, 2026, and the winning applicant will be announced on April 15, 2026. By inviting students to reflect on their motivations and long-term goals, the Dr. Louis Krenn Scholarship for Medical Students serves as a platform to elevate voices that are shaping the next era of healthcare. With a clear focus on values that matter most in medicine, this scholarship honors the journey of becoming a physician and recognizes the essential human connection that underpins the practice. The scholarship also underscores a broader vision: to encourage thoughtful leadership in medicine. Dr. Louis Krenn believes that by supporting students at the earliest stages of their careers, the field of medicine will continue to evolve with greater empathy, ingenuity, and resilience. This annual initiative is one of many ways Dr. Louis Krenn remains committed to nurturing future leaders in medicine. It reflects his deep belief that the future of healthcare depends not only on science and technology, but also on the strength of those who choose to serve through medicine. About Dr. Louis Krenn Dr. Louis Krenn earned his medical degree from the University of Arkansas for Medical Sciences and completed his Family Medicine residency at Cox Family Medicine Residency Program. He has served in numerous leadership positions at CoxHealth and continues to be actively involved in clinical practice and medical education. His work stands as a testament to his belief in excellence, compassion, and continuous growth within the healthcare profession. Media Contact Company Name: Dr. Louis Krenn Scholarship Contact Person: Dr. Louis Krenn Email: Send Email City: Springfield State: Missouri Country: United States Website:
